Fierce Pharma

MAY 22, 2024

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year.

126

126

Pharmacy Times

JANUARY 10, 2023

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

132

132

STAT

DECEMBER 11, 2024

The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027. Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. Read the rest…

Vaccines 145

Vaccines 145

Fierce Healthcare

OCTOBER 15, 2024

Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a ro | Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore (..)

137

137

Pharmaceutical Technology

AUGUST 31, 2023

Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.

52

52

Fierce Healthcare

MARCH 21, 2023

by 2027: report pminemyer Tue, 03/21/2023 - 16:11 The payer services market could be worth $118.2B

52

52

BioPharm

OCTOBER 26, 2023

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.

98

98

Fierce Pharma

AUGUST 16, 2024

Novo Nordisk Pharmatech expects the plant to be complete by 2027. billion Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make raw materials, the company said Friday. The project will result in the creation of 50 new jobs, according to the company.

124

124

Drug Store News

JANUARY 30, 2023

The underlying growth rate will be driven by new drug launches and wider use of recently launched brands despite efforts by payers to constrain their budgets, and the impact of lower-cost options.

96

96

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

110

110

STAT

SEPTEMBER 23, 2024

1, and the negotiated prices of those drugs take effect in 2027.  Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs. Medicare will announce that list by Feb.

Specialty Pharmacies 134

Specialty Pharmacies 134

STAT

OCTOBER 26, 2023

About 800,000 nurses plan to leave the workforce by 2027, and more than half of newly graduated nurses are leaving the profession within two years. The Kaiser strike is over, for now, but there is no clear resolution in place, and other strikes are still under way or on the horizon.

Insurance 134

Insurance 134

STAT

SEPTEMBER 12, 2024

billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate. Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1

Vaccines 131

Vaccines 131

Drug Store News

APRIL 12, 2023

17, 2027, or earlier based on certain circumstances. Under the agreement, Dr. Reddy’s has the right to market its product beginning Nov.

98

98

Pharmaceutical Commerce

AUGUST 19, 2024

The 86,000 square-foot Køge facility will be fully functional by 2027.

81

81

Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

75

75

Fierce Pharma

DECEMBER 20, 2023

The sale is expected to go into effect in January 2027. . | In a deal worth around $116 million, Novartis is handing over a portfolio of “select ophthalmology brands” to Mumbai’s J.B. Chemicals & Pharmaceuticals. Until then, J.B. plans to distribute and market the medicines in India.

98

98

STAT

DECEMBER 7, 2023

One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.

FDA 128

FDA Compounding Pharmaceutical Companies Pharmaceutical Companies 128

Outsourcing Pharma

OCTOBER 24, 2023

Traditionally, the pharmaceutical landscape has been dominated by small molecules.

64

64

STAT

JULY 24, 2023

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging 98

Packaging Insurance Hospitals 98

STAT

JANUARY 17, 2023

The number of health care-related artificial intelligence models on the market has increased steadily over the past decade, with the health care AI market expected to grow from $7 billion today to $67 billion in 2027.

101

101

The Guardian - Pharmaceutical Industry

SEPTEMBER 21, 2023

The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).

97

97

Pharmaceutical Commerce

APRIL 5, 2023

Rise in value attributed to the ongoing decentralization of pharmacies.

52

52

STAT

DECEMBER 13, 2024

The nonprofit Howard Hughes Medical Institute (HHMI) will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for a round of funds to be awarded in 2027.

66

66

Fierce Pharma

SEPTEMBER 4, 2024

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team, a slimdown of its R&D program and decisive action on the future of | The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity covering (..)

52

52

STAT

OCTOBER 3, 2024

1, 2025, the Centers for Medicare and Medicaid Services will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.

99

99

European Pharmaceutical Review

AUGUST 27, 2024

Manufacturing of the biologic products in the expanded Sweden Biomanufacturing Center is planned to begin from Q4 of 2027, according to AstraZeneca. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden”, Alfredsson continued.

115

115

Fierce Healthcare

APRIL 4, 2024

Sacramento, California-based Sutter Health is getting called up to the big leagues next summer when the Oakland Athletics take up residence at a minor league park bearing its name. |

59

59

European Pharmaceutical Review

NOVEMBER 2, 2022

Somewhat ambitious: Meet three percent of GDP by 2027, building on aspirations set out by the Confederation of British Industry (CBI), the European Commission (EC) and opposition political parties. The government would need to invest an extra £1 billion in R&D by 2027. Private investment would also need to rise by £0.8

Communication 98

Communication 98

pharmaphorum

NOVEMBER 25, 2020

Jefferies expects that the company expects sales of $14 billion could be at risk by 2027 from patent expiries of Tasigna, Promacta, Jakavi, Gilenya and Entresto. In the short term, the analysts predict “flattish” Q4 sales, although they noted that the company may benefit from cost savings introduced during the COVID-19 pandemic.

Hospitals 119

Hospitals 119

Pharmaceutical Technology

OCTOBER 6, 2023

Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.

59

59

Pharmaceutical Commerce

AUGUST 30, 2024

The 3PL plans to convert all its trucks to electric by 2027.

52

52

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

106

106

European Pharmaceutical Review

FEBRUARY 27, 2024

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies FDA 105

Pharmaceutical Technology

MAY 23, 2024

The cost saving programme is expected run over multiple years and will save the company about $1.5bn by 2027.

52

52

STAT

NOVEMBER 20, 2023

Under the new agreement, the level of allowed growth in drug sales will increase from 2% in 2024 to 4% by 2027. The current plan, which has drawn the ire of pharma companies, requires drug companies to pay rebates back to the U.K. if spending on medicines increases by more than 2% a year. Continue to STAT+ to read the full story…

109

109

Pharmaceutical Commerce

JANUARY 25, 2023

Annual report finds continuing impact of COVID-19 on global markets

52

52